SAN DIEGO, April 2, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will present additional data from a double-blind analysis of the first year of treatment from its two-year Phase II clinical trial of MN-166, a novel, orally administered compound being evaluated for the treatment of multiple sclerosis (MS), at the 18th Meeting of the European Neurological Society to be held in Nice, France from June 7 to 11, 2008.
